⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
IMVT News
Immunovant, Inc. Common Stock
Peripheral T-Cell Lymphoma Market to Witness Significant Expansion at a CAGR of 7% During the Forecast Period (2026–2036) Amid Advancing Treatment Landscape | DelveInsight
globenewswire.com
MRK
IPHA
VERU
KURA
INCY
AMGN
PFE
GILD
REGN
AZN
CRSP
BIIB
NTRA
ALLO
KYMR
ADCT
IMUX
CELC
ONON
ABBV
TDOC
BMY
IMVT
GNTX
IMPP
AUTL
Follicular Lymphoma Clinical Trial Space Intensifies with 45+ Companies in Active Development | DelveInsight
globenewswire.com
AZN
CRSP
NKTR
INCY
IPHA
ABBV
BIIB
ALKS
IMVT
CLRB
IMPP
REGN
THO
AUTL
KYMR
CBIO
GILD
Generalized Myasthenia Gravis Market on the Brink of Change: 8 Promising Late-Stage Drugs Signal a New Treatment Era | DelveInsight
globenewswire.com
IMVT
ROIV
CART
NVS
MRK
REGN
UCB
JNJ
AMGN
ARGX
KYMR
CABA
BMY
BHVN
Immunovant Announces Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED)
globenewswire.com
IMVT
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Immunovant, Inc. (NASDAQ: IMVT)
prnewswire.com
IMVT
Immunovant Provides Corporate Updates and Reports Financial Results for the Third Quarter Ended December 31, 2025
globenewswire.com
IMVT
Immunovant to Report Financial Results for the Third Quarter Ended December 31, 2025, and Provide Business Update on Friday, February 6, 2026
globenewswire.com
IMVT
ROIV
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Immunovant, Inc. (NASDAQ: IMVT)
prnewswire.com
IMVT
Immunovant Announces Pricing of $550 Million Common Stock Financing
globenewswire.com
IMVT
Immunovant Provides Corporate Updates and Reports Financial Results for the Second Quarter Ended September 30, 2025
globenewswire.com
IMVT